

CITATION REPORT

List of articles citing

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial

DOI: 10.1016/j.medj.2020.04.001
Med, 2020, 1, 105-113.e4.

Source: <https://exaly.com/paper-pdf/84441116/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
216	Factors associated with clinical outcomes in patients with Coronavirus Disease 2019 in Guangzhou, China. 2020 , 133, 104661		5
215	Impact of COVID-19 on people living with HIV: A review. 2020 , 6, 100019		27
214	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. 2020 , 225, 152008		39
213	Repurposing Existing Drugs for the Treatment of COVID-19. 2020 , 17, 1186-1194		15
212	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. 2020 , 8, 384		7
211	Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation. 2020 , 257, 118114		39
210	COVID-19 and chronic obstructive pulmonary disease: therapeutic potential of blocking SARS-CoV2 adhesion factors. 2020 , 50, 1153-1154		1
209	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. 2020 , 2, 1-12		11
208	Safety perspectives on presently considered drugs for the treatment of COVID-19. 2020 , 177, 4353-4374		9
207	. 2020 , 192, E1585-E1596		2
206	Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis. 2020 , 5,		24
205	The "sex gap" in COVID-19 trials: a scoping review. 2020 , 29, 100652		21
204	COVID-19: A review of the proposed pharmacological treatments. 2020 , 886, 173451		54
203	Emerging Therapeutic Modalities against COVID-19. 2020 , 13,		11
202	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. 2020 , 13, 1187-1195		46
201	Evaluation of Current Therapies for COVID-19 Treatment. 2020 , 8,		9
200	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. 2020 , 21,		27

199	Drug treatments for covid-19: living systematic review and network meta-analysis. 2020 , 370, m2980	331
198	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. 2020 , 26, 2181-2189	27
197	COVID-19: Clinical aspects and therapeutics responses. 2020 , 28, 1004-1008	25
196	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients. 2020 , 11, 582348	11
195	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508	165
194	Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). 2020 , 7, 41	37
193	[COVID-19, management, therapeutic and vaccine approaches]. 2020 , 59, 27-33	1
192	Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2020 , 17, e1003293	36
191	SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. 2020 , 38, 2405-2415	10
190	Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. 2020 , 37, 4107-4131	2
189	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
188	Is there any potential management against COVID-19? A systematic review and meta-analysis. 2020 , 28, 765-777	9
187	A Narrative Review of Emerging Therapeutics for COVID-19. 2020 , 4, 745-758	5
186	Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. 2020 , 20, 954	64
185	A systematic review assessing the under-representation of elderly adults in COVID-19 trials. 2020 , 20, 538	17
184	Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19. 2020 , 7, 616341	38
183	Coronavirus pandemic: treatment and future prevention. 2020 , 15, 1507-1521	1
182	A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection. 2020 , 86, 104610	13

181	Immunology of COVID-19: Current State of the Science. 2020 , 52, 910-941	962
180	Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. 2020 , 43, 809-821	34
179	Oral Methioninase for Covid-19 Methionine-restriction Therapy. 2020 , 34, 1593-1596	5
178	COVID-19 infection: the China and Italy perspectives. 2020 , 11, 438	49
177	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. 2020 , 56, 106054	168
176	COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). 2020 , 56, 106080	96
175	Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. 2020 , 8, 355	20
174	What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials. <i>Med</i> , 2020 , 1, 9-10	31.7 5
173	Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. 2020 , 286, 198073	25
172	Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China. 2020 , 92, 1922-1931	11
171	An overview on the use of antivirals for the treatment of patients with COVID19 disease. 2021 , 30, 45-59	1
170	Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. 2021 , 44, 43-53	16
169	Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. 2021 , 93, 775-785	11
168	Primed for global coronavirus pandemic: Emerging research and clinical outcome. 2021 , 209, 112862	10
167	Characteristics of SARS-CoV-2 and COVID-19. 2021 , 19, 141-154	1287
166	COVID 19 and liver: An A-Z literature review. 2021 , 53, 146-152	30
165	Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review. 2021 , 19, 679-687	8
164	Reporting and design of randomized controlled trials for COVID-19: A systematic review. 2021 , 101, 106239	1



163	Decoding information on COVID-19: Ontological approach towards design possible therapeutics. 2021 , 22, 100486	1
162	A retrospective comparison of drugs against COVID-19. 2021 , 294, 198262	2
161	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of , , and clinical trials. 2021 , 11, 1207-1231	17
160	Emerging treatment strategies for COVID-19 infection. 2021 , 21, 167-179	81
159	Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. 2021 , 102, 275-281	7
158	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. 2021 , 11, 45-52	22
157	Old Drugs for New PurposeFast Pace Therapeutic Identification for SARS-CoV-2 Infections by Pharmacophore Guided Drug Repositioning Approach. 2021 , 42, 212-226	5
156	HIV-1 Infection Does Not Change Disease Course or Inflammatory Pattern of SARS-CoV-2-Infected Patients Presenting at a Large Urban Medical Center in New York City. 2021 , 8, ofab029	5
155	Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. 2020 , 11, 630500	15
154	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. 2020 , 11, 583914	4
153	An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. 2021 , 10, 1945	2
152	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. 2020 , 11, 616595	8
151	Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology. 2021 , 22, 254-281	17
150	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. 2021 , 12, 607408	10
149	SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack. 2021 , 13, 361-375	3
148	Current evidence for COVID-19 therapies: a systematic literature review. 2021 , 30,	11
147	A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. 2021 , 19, e3001128	25
146	Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2. 2021 , 12, 655528	5

145	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. 2021 , 12, 1517	24
144	Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2021 , 16, e0248132	20
143	Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19. 2021 , 13, e13687	
142	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. 2021 , 17, 24	7
141	Repositioned Drugs for COVID-19-the Impact on Multiple Organs. 2021 , 3, 1-18	3
140	Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. 2021 , 13, 10833-10852	1
139	No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. 2021 , 12, 621676	0
138	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. 2021 ,	
137	The time to offer treatments for COVID-19. 2021 , 30, 505-518	9
136	Confronting the COVID-19 Pandemic: December 2019–May 2020. 1-28	
135	Efficiency of antiviral treatment in COVID-19. 2021 , 21, 648	11
134	A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. 2021 , 5, 815-829	62
133	Exploring status of emergency drugs and vaccine development in Covid-19 pandemic: an update. 2021 , 32, 1-13	3
132	Therapeutic strategies to fight COVID-19: Which is the status artis?. 2021 ,	12
131	How COVID-19 has fundamentally changed clinical research in global health. 2021 , 9, e711-e720	20
130	The Role of Advanced Technologies Supplemented with Traditional Methods in Pharmacovigilance Sciences. 2021 , 15, 34-50	3
129	Mechanism involved in the pathogenesis and immune response against SARS-CoV-2 infection. 2021 , 32, 1-9	3
128	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. 2021 , 14,	10

127	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. 2021 , 8, 639970	9
126	Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. 2021 , 51, 912-920	9
125	COVID-19 impact on the liver. 2021 , 9, 3814-3825	6
124	Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. 2021 , 14, 740-748	17
123	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. 2021 , 10,	2
122	Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients. 2021 , 12, 580989	1
121	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. 2021 ,	12
120	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. 2021 , 11,	6
119	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. 2021 , 9,	9
118	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. 2021 , 2021, 1-22	0
117	Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study. 2021 , 11, 05017	1
116	Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. 2021 , 61, 3771-3788	6
115	Clinical and virological course of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center cohort study. 2021 , 18, 147	1
114	Effectiveness of favipiravir in COVID-19: a live systematic review. 2021 , 40, 2575-2583	12
113	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. 2021 , 12, 699949	7
112	Drug-Induced Liver Disturbance During the Treatment of COVID-19. 2021 , 12, 719308	4
111	Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. 2021 , 1-12	3
110	Novel approaches for COVID-19 diagnosis and treatment: a nonsystematic review. 2021 , 45, 358-371	0

109	Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis. 2021 , 9, 1197-1208	6
108	Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. 2021 , 4,	2
107	Discovery of Novel Small-Molecule Inhibitors of SARS-CoV-2 Main Protease as Potential Leads for COVID-19 Treatment. 2021 , 61, 4745-4757	3
106	Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications.. 2021 , 4, 215-230	0
105	In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals. 2021 , 109, 108038	1
104	Current status of therapeutic alternatives for COVID-19: A narrative review.. 2021 , 29, 312-327	2
103	Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors. 2021 , 167, 106012	2
102	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. 2021 , 23, 6364-6376	4
101	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. 2021 , 9, 729559	7
100	Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis. 2021 , 28, 59570-59593	5
99	Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. 2021 , 1, 252-284	7
98	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. 2021 , 12, 752227	5
97	Abstracts for reports of randomised trials of COVID-19 interventions had low quality and high spin. 2021 , 107-120	4
96	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. 2021 , 139, 68-79	3
95	Experimental Pharmacotherapy for COVID-19: The Latest Advances. 2021 , 13, 1-13	14
94	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. 2021 , 10, 93-113	9
93	COVID-19 Antiviral and Treatment Candidates: Current Status. 2021 , 21, e7	5
92	SARS-CoV-2 therapeutics: how far do we stand from a remedy?. 2021 , 73, 750-768	6

91	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. 2021 , 53, 166-219	11
90	Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. 2021 , 9, e00705	17
89	Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract. 2021 , 9, e00698	7
88	Therapeutics for COVID-19: established and in development. 2020 , 41, 217	2
87	Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics.	39
86	Lopinavir-Ritonavir in treatment of COVID-19: A dynamic systematic benefit-risk assessment.	0
85	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19.	2
84	Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.	1
83	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).	2
82	An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario. 2020 , 31,	8
81	Possibilities for correcting hepatotoxic reactions during therapy in patients with COVID-19 (case report). 2020 , 7, 65-72	2
80	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. 2020 , 13, 4673-4695	20
79	Pharmacological treatment of COVID-19: an update.	1
78	Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19. 2020 , 65, 27-30	8
77	Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence. 2020 , 52, 317-334	6
76	Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. 2020 , 52, 313-323	14
75	Current Approaches to COVID-19: Therapy and Prevention. 2020 , 24, 838-846	10
74	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. 2020 , 24, 1106-1113	1

73	An overview of potential therapeutic agents to treat COVID-19. 2020 , 14, 318-327	4
72	Evaluation of the Efficacy of Arbidol in Comparison with the Standard Treatment Regimen of Hospitalized Patients with Covid-19: A Randomized Clinical Trial. 2020 , 15,	2
71	Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. 2020 , 32, 166-196	22
70	Disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic in March-October 2020: An exploratory analysis. 2021 , 16, e0245103	0
69	Interferon- α induced anemia in severe coronavirus disease 2019 patients: a single centered, retrospective study. 2021 , 43, 644-650	
68	Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition. 2021 ,	7
67	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. 2021 ,	0
66	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. 2021 , 144, 112276	3
65	Therapeutic Approach to Coronavirus Disease. 2020 , 67-97	0
64	COVID-19 Drug Repositioning: Present Status and Prospects. 2022 , 645-671	0
63	Current evidence for COVID-19 therapies: a systematic literature review.	
62	A Systematic Review and Network Meta-Analysis for COVID-19 Treatments.	
61	Evidence of the Clinical Efficacy of Antiviral Agents against SARS-CoV-2. 2021 , 10, 94-111	0
60	Management of COVID-19: A brief overview of the various treatment strategies. 2020 , 3, 233	1
59	 SARS-COV-2, 	0
58	Rationale and prognosis of repurposed drugs with risk stratification of COVID-19 patients requiring Oxygen supplementation: A systematic review and meta-analysis.	
57	Analysis of Structure, Mechanism of Action and Efficacy of Potential and Ideal COVID-19 Treatments. 2020 , 1, 197-208	
56	Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses.	

55	Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol. 2020 , 8, 1527	2
54	A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. 2021 , 13, 163-171	1
53	Insight into the role of hydrochloric acid in the thermodynamics and nucleation kinetics behavior of Arbidol hydrochloride monohydrate from metastable zone widths.	0
52	Pharmacoeconomic Analysis of Treatment Regimens for Coronavirus Infection Coronavirus Disease-19. 2021 , 9, 1182-1189	0
51	Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review. 2021 , 14, 8557-8571	9
50	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. 2021 , 22, 304	0
49	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. 2021 , 10, 1-32	0
48	Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019. 2021 ,	1
47	A Narrative Review of Existing Options for COVID-19-Specific Treatments. 2021 , 2021, 8554192	
46	Investigation of Thiocarbamates as Potential Inhibitors of the SARS-CoV-2 Mpro. 2021 , 14,	
45	Safety profile assessment of drug products used for the pathogenetic treatment of COVID19. 2021 , 23, 314-329	
44	COVID-19: Gastrointestinal manifestations, liver injury and recommendations.. 2022 , 10, 1140-1163	1
43	Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.. 2022 , 22, 107	7
42	Safety profile of COVID-19 drugs in a real clinical setting.. 2022 , 1	3
41	Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis.. 2021 ,	2
40	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.. 2022 , 58,	0
39	Evaluation of Hepatic Biochemical Parameters during Antiviral Treatment in COVID-19 Patients.. 2021 , 11,	3
38	Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing Data. 2020 ,	

37	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.. 2022 , e13763	1
36	Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study.. 2022 , 12, e055137	1
35	Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.. 2022 , 12, e048502	3
34	Patterns of liver profile disturbance in patients with COVID-19.. 2022 , 10, 2063-2071	0
33	Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study.. 2022 , 11,	0
32	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro.. 2022 , 17, 40	0
31	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases.. 2021 , 13, 1850-1874	1
30	Modeling the Structure-Activity Relationship of Arbidol Derivatives and Other SARS-CoV-2 Fusion Inhibitors Targeting the S2 Segment of the Spike Protein.. 2021 , 61, 5906-5922	0
29	A Recent Update on Advanced Molecular Diagnostic Techniques for COVID-19 Pandemic: An Overview.. 2021 , 12, 732756	9
28	Discriminant models for the prediction of postponed viral shedding time and disease progression in COVID-19.. 2022 , 22, 366	0
27	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.. 2022 ,	0
26	Image_1.JPEG. 2020 ,	
25	A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. 2021 , 13, 163	2
24	Preferential Solvation, Hansen Solubility Parameters, and Thermodynamic Behaviors of 1-Methyl-2-[(phenylthio)methyl]-3-carbethoxy-4-[(dimethylamino)methyl]-5-hydroxy-6-bromoindole Hydrochloride Monohydrate in Four Aqueous Binary Solvents. 2022 , 67, 1276-1298	1
23	Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARS-CoV-2 patients in South Korea: A retrospective cohort study.. 2022 , 17, e0267645	0
22	Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals. 2022 ,	1
21	Keeping up with the COVID-19. Could siRNA-based antivirals be a part of the answer?. 20220012	0
20	Acute Kidney Injury in COVID-19 Patients: Pathogenesis, Clinical Characteristics, Therapy, and Mortality. 2022 , 10, 53	2

19	Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review. Volume 15, 4457-4466	2
18	Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties. 2022 , 12,	1
17	Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis.	1
16	Recent advances in small-molecular therapeutics for COVID-19.	0
15	Ultra-Large-Scale Screening of Natural Compounds and Free Energy Calculations Revealed Potential Inhibitors for the Receptor-Binding Domain (RBD) of SARS-CoV-2. 2022 , 27, 7317	1
14	Mechanism of N-0385 blocking SARS-CoV-2 to treat COVID-19 based on molecular docking and molecular dynamics. 13,	0
13	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. 1-12	0
12	Lopinavir and Ritonavir have a high affinity to SARS-CoV-2 S-protein Receptor-Binding Domain sequenced in Brazil.	0
11	Lung-on-chip microdevices to foster pulmonary drug discovery.	0
10	Integrative transcriptome analysis of SARS-CoV-2 human-infected cells combined with deep learning algorithms identifies two potential cellular targets for the treatment of coronavirus disease.	0
9	Synthesis, Crystal Structure, Hirshfeld Surface and Docking Studies of 2-(methacryloyloxy)ethyl-6-amino-5-cyano-2-methyl-4-(thiophen-2-yl)-4 H -pyran-3-carboxylate. 2022 , 7,	0
8	The effect of Fingolimod on patients with moderate to severe COVID -19. 2023 , 11,	0
7	The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients. 2023 , 11, 398	0
6	A Practical Approach in Refining Binary Outcome for Treatment Effect of COVID-19 According to Geographical Diversity. 2023 , 8, 83	0
5	A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. 2023 , 11, 332	0
4	Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches. 2023 , 95,	0
3	Effect of SARS-CoV-2 infection on the liver. 12, 109-121	0
2	Autoimmune liver diseases and SARS-CoV-2. 29, 1838-1851	0

- 1 Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives. **2023**, 1-16

○